Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

证券代码：000963 证券简称：华东医药 华东医药股份有限公司投资者关系活动记录表 12.29%，环比2024年第四季度增长24.37%，整体经营符合第一季度计 划目标。国内医美全资子公司欣可丽美学积极拓展国内市场，报告期 内实现营业收入2.54亿元，同比下降1.36%，环比2024年第四季度增长 10.64% 。公司持续深化国内高端医美产品布局，高端玻尿酸 MaiLi®Extreme（商品名：魅俪®朔盈®）将于2025年5月正式实现商业化 销售；多功能面部皮肤管理平台Préime DermaFacial也将于2025年内正 式实现商业化销售。此外，重组A型肉毒毒素YY001、能量源设备V30 及Ellansé®伊妍仕®M型等核心医美产品国内上市申请均已获受理，有 望于2026年获批。依托国内差异化医美产品矩阵的持续丰富，叠加消 费升级带来的市场需求扩容，公司国内医美业务成长潜能将加速释放。 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □业绩说明会 □媒体采访 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 ☑其他 ...

Core Viewpoint - The company reported a stable growth in revenue and net profit for the first quarter of 2025, with significant contributions from its core subsidiaries and innovative drug sales, despite facing challenges in the medical aesthetics sector [6][10]. Financial Performance - The company achieved operating revenue of 10.736 billion yuan, a year-on-year increase of 3.12% and a quarter-on-quarter increase of 2.95% [6]. - The net profit attributable to shareholders was 915 million yuan, up 6.06% year-on-year, while the net profit excluding non-recurring gains and losses reached 897 million yuan, marking a historical high with a 7.04% increase year-on-year [6]. - The core subsidiary, China Medical East, reported operating revenue of 3.621 billion yuan, a 6.52% increase year-on-year, and a net profit of 843 million yuan, up 12.20% [7]. Business Segments - The pharmaceutical segment showed strong performance with innovative drug sales driving growth, particularly the CAR-T product and biosimilar drugs, which have gained significant market traction [7][8]. - The medical aesthetics segment faced challenges due to economic conditions and increased competition, with revenue from the UK subsidiary Sinclair declining by 12.29% year-on-year [10]. - The industrial microbiology segment experienced rapid growth, with a year-on-year increase of 29.98% [11]. R&D Progress - The company increased its R&D investment to 880 million yuan, a 49.60% year-on-year rise, with direct R&D expenses reaching 600 million yuan, up 71.77% [12]. - Significant milestones were achieved in the development of innovative drugs, including approvals and clinical trials for various oncology and metabolic disease treatments [12][15]. Market Expansion - The company is actively expanding its market presence, with over 70 insurance plans covering its CAR-T product, which is expected to sustain high growth [7]. - The acquisition of Guizhou Hengba Pharmaceutical has shown promising results, with revenue exceeding 24.26 million yuan and net profit of 6.67 million yuan in the reporting period [8].

Group 1: Aier Eye Hospital - In 2024, Aier Eye Hospital achieved an outpatient volume of 16.94 million, a year-on-year increase of 12.14% [1] - The company reported a total revenue of 20.98 billion yuan, reflecting a growth of 3.02% compared to the previous year [2] - The net profit attributable to shareholders was 3.56 billion yuan, up by 5.87% year-on-year [2] - The company introduced several advanced medical technologies and products, including the INTENSITY™ intraocular lens and new dry eye treatment technology [1][3] Group 2: Tonghuashun - Tonghuashun reported a revenue of 4.19 billion yuan in 2024, marking a 17.47% increase from the previous year [5] - The net profit attributable to shareholders reached 1.82 billion yuan, a significant growth of 30% year-on-year [4][5] - The increase in revenue and profit was primarily driven by a recovery in the securities market and rising demand for financial information services [4] Group 3: Yiwei Lithium Energy - Yiwei Lithium Energy achieved a revenue of 1.28 billion yuan in Q1 2025, with a net profit of 110.11 million yuan, reflecting a 16.60% increase in net profit [7] - The company reported a significant increase in the shipment of energy storage batteries, with a year-on-year growth of 80.54% [8] - The company is expanding into emerging markets such as eVTOL and drones, with ongoing projects and production facilities being established [9] Group 4: Huadong Medicine - Huadong Medicine reported a revenue of 10.74 billion yuan in Q1 2025, a 3.12% increase year-on-year [10] - The net profit attributable to shareholders was 914.71 million yuan, up by 6.06% compared to the same period last year [11] - The company achieved its highest historical level of net profit excluding non-recurring gains and losses, reaching 897.34 million yuan [10] Group 5: Muyuan Foods - Muyuan Foods reported a revenue of 36.06 billion yuan in Q1 2025, a year-on-year increase of 37.26% [17] - The company turned a profit with a net profit of 44.91 billion yuan, compared to a loss of 23.79 billion yuan in the same period last year [18] - The significant growth was attributed to increased pig prices and sales [17] Group 6: China Aluminum - China Aluminum reported a revenue of 55.78 billion yuan in Q1 2025, with a net profit of 3.54 billion yuan, reflecting a year-on-year increase of 58.78% [21] - The company successfully managed market price fluctuations, resulting in increased product sales and profits [21] Group 7: Hengrui Medicine - Hengrui Medicine achieved a revenue of 72.06 billion yuan in Q1 2025, a 20.14% increase year-on-year [22] - The net profit attributable to shareholders was 18.74 billion yuan, up by 36.9% compared to the previous year [22] - The increase in profit was significantly influenced by a licensing payment received during the reporting period [22] Group 8: Bull Group - Bull Group reported a revenue of 16.83 billion yuan in 2024, reflecting a 7.24% increase year-on-year [13] - The net profit attributable to shareholders was 4.27 billion yuan, a growth of 10.39% compared to the previous year [13] - The company experienced growth in its electrical connection and smart lighting businesses, as well as rapid development in its new energy sector [14]

Core Insights - Huadong Medicine (000963) reported a stable growth trend in Q1 2025, achieving operating revenue of 10.736 billion yuan, a year-on-year increase of 3.12%, and a net profit attributable to shareholders of 915 million yuan, up 6.06% [1] - The company's core pharmaceutical industrial segment continued to perform well, with its subsidiary, China-U.S. Huadong, generating revenue of 3.621 billion yuan, a 6.52% increase, and a net profit of 843 million yuan, up 12.20% [1] - The sales of innovative drugs, particularly the biosimilar drug Ustinumab injection (Sailixin), have shown strong market performance, with over 800 hospitals prescribing it as of March 31, 2025 [1] Business Segments - The pharmaceutical industrial R&D investment reached 880 million yuan in Q1 2025, a 49.60% increase year-on-year, with direct R&D spending of 600 million yuan, up 71.77%, accounting for 16.67% of pharmaceutical industrial revenue [2] - Huadong Medicine is focusing its innovative R&D efforts on three key areas: endocrinology, autoimmune diseases, and oncology, with several important milestones achieved in Q1 2025 [2] - The medical aesthetics segment generated approximately 238 million yuan in revenue in Q1 2025, reflecting a 24.37% increase compared to Q4 2024, with 40 high-end products in the international market [2]

证券代码：000963 证券简称：华东医药 公告编号：2025-035 华东医药股份有限公司 第十届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十届监事会第二十 三次会议的通知于 2025 年 4 月 21 日以书面和电子邮件等方式送达 各位监事，于 2025 年 4 月 24 日（星期四）在公司会议室以现场并结 合通讯方式召开。会议应参加监事 6 人，实际参加监事 6 人。会议由 公司监事会主席主持，会议的召开和表决程序符合《公司法》、《公 司章程》的有关规定，会议合法有效。 二、监事会会议审议情况 监事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： 审议通过《关于公司<2025年第一季度报告>的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn） 的公司《2025 年第一季度报告》。 表决结果：6 票同意，0 票反对，0 票弃权。 三、备查文件 第十届监事会第二十三次会议决议。 特此公告。 华东医药股份有限公司监 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-034 华东医药股份有限公司 第十届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十届董事会第三 十三次会议的通知于2025年4月21日通过书面和邮件等方式送达各位 董事，于2025年4月24日（星期四）在公司会议室以现场结合通讯的 方式召开。会议应参加董事9名，实际参加董事9名。会议由董事长主 持。会议的召开和表决程序符合《公司法》、《公司章程》的有关规 定，会议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： 审议通过《关于公司<2025年第一季度报告>的议案》 经审议，董事会认为《2025年第一季度报告》的内容真实、准确、 完整地反映了公司2025年第一季度经营的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏，报告编制和审核的程序符合法律、 行政法规和中国证监会的相关规定。具体内容详见公司同日披露于巨 潮资讯网（http://www. ...

Core Insights - The company reported a stable growth trend in Q1 2025, with revenue of 10.736 billion yuan, a year-on-year increase of 3.12%, and a net profit of 915 million yuan, up 6.06% [1] - The pharmaceutical industrial sector continues to be a key growth driver, with core subsidiary China East Pharmaceutical achieving revenue of 3.621 billion yuan, a 6.52% increase, and a net profit of 843 million yuan, up 12.20% [2] - The company is focusing on innovation, with over 80 projects in its pipeline, and has significantly increased R&D investment by 49.60% to 880 million yuan in Q1 2025 [4] Business Segments - The innovative drug sales in the pharmaceutical industrial sector are gaining momentum, particularly with the expansion of reimbursement indications for the Bai Ling series products [2] - The CAR-T product, Zewokaiolun, has shown strong sales performance, with over 200 certified medical institutions and 154 effective orders placed by the partner company [3] - The company’s self-developed GLP-1 receptor agonist, HDM1002, has entered the final stages of clinical trials, indicating a robust pipeline in the endocrine field [5][6] Medical Aesthetics - The medical aesthetics segment is showing resilience, with the subsidiary Sinclair achieving approximately 238 million yuan in revenue, a 24.37% increase from the previous quarter [9] - The company has a portfolio of 40 high-end medical aesthetic products, with 26 already launched globally, indicating a strong market presence [9] - New products in the medical aesthetics field, including injectable products, are expected to drive further growth in 2025 [10] Future Outlook - The company aims to leverage its innovative capabilities and product differentiation to expand its market share in the medical aesthetics sector, which is projected to grow steadily [12] - The pharmaceutical industrial sector is expected to maintain a strong growth trajectory, supported by ongoing market expansion and product pipeline development [12] - The overall performance in Q1 2025 reflects the company's commitment to innovation and growth, positioning it for future success in the pharmaceutical and medical aesthetics industries [12]

Financial Performance - The company's revenue for Q1 2025 was ¥10,735,787,899.82, representing a 3.12% increase compared to ¥10,410,809,128.72 in the same period last year[5]. - Net profit attributable to shareholders was ¥914,708,484.70, up 6.06% from ¥862,411,560.96 year-on-year[5]. - Basic earnings per share increased by 5.98% to ¥0.5224 from ¥0.4929 in the same period last year[5]. - The company achieved a revenue of 10.736 billion RMB, representing a year-on-year growth of 3.12% and a quarter-on-quarter increase of 2.95%[15]. - The net profit attributable to shareholders reached 915 million RMB, up 6.06% year-on-year, with a historical high of 897 million RMB in net profit after deducting non-recurring items, reflecting a 7.04% increase[15]. - The total comprehensive income for the current period is CNY 996,029,155.89, compared to CNY 900,835,055.99 in the previous period, reflecting an increase of approximately 10.6%[36]. - Operating profit for the current period is CNY 1,132,257,266.34, up from CNY 1,072,095,809.87, indicating a growth of about 5.6%[35]. Cash Flow and Assets - The net cash flow from operating activities decreased by 71.87%, amounting to -¥832,728,693.88, compared to -¥484,522,666.13 in the previous year[5]. - The company’s cash and cash equivalents decreased to ¥3,711,981,117.29 from ¥5,276,440,245.36, representing a decline of 29.66%[31]. - Accounts receivable increased significantly to ¥11,558,233,812.68 from ¥8,425,358,862.23, marking a growth of 37.80%[31]. - The company’s total assets reached ¥39,447,159,682.31, up from ¥37,879,046,367.15, indicating a growth of 4.15%[33]. - Cash flow from operating activities shows a net outflow of CNY -832,728,693.88, worsening from CNY -484,522,666.13 in the previous period[38]. - Cash and cash equivalents at the end of the period stand at CNY 3,421,628,769.05, an increase from CNY 3,105,149,941.54 in the previous period[38]. Research and Development - Research and development expenses rose by 82.99% to ¥51,537.69 million, compared to ¥28,163.98 million in the previous year[10]. - The company invested 880 million yuan in pharmaceutical R&D, a year-on-year increase of 49.60%, with direct R&D expenses of 600 million yuan, up 71.77%[20]. - Research and development expenses increased significantly to CNY 515,376,918.47 from CNY 281,639,751.64, marking an increase of about 83.1%[35]. Market Performance and Product Development - The core subsidiary, China Medical East, reported a revenue of 3.621 billion RMB, a year-on-year increase of 6.52%, and a net profit of 843 million RMB, up 12.20%[16]. - The CAR-T product, Zewokizumab, has been rapidly adopted in over 70 commercial insurance plans, significantly reducing patient costs and is expected to maintain high growth[16]. - The biosimilar drug, Selumetinib, has been prescribed in over 800 hospitals since its launch, indicating strong market performance and expected continued growth throughout the year[17]. - The new drug, Proglumetacin, has been included in the national medical insurance directory, with increasing hospital admissions, enhancing the company's competitive edge in the diabetes SGLT-2 segment[17]. - The acquisition of Guizhou Hengba Pharmaceutical has resulted in a revenue of 24.26 million RMB, with a net profit of 6.67 million RMB, marking over 100% growth year-on-year[17]. - The pharmaceutical commercial segment achieved a revenue of 6.934 billion RMB, reflecting a year-on-year growth of 3.23% and a net profit of 115 million RMB, up 7.33%[18]. - The aesthetic medicine segment faced growth pressure with a consolidated revenue of approximately 238 million yuan, a year-on-year decrease of 12.29%, but a quarter-on-quarter increase of 24.37%[19]. - The domestic aesthetic medicine subsidiary achieved a revenue of 254 million yuan, a year-on-year decline of 1.36%, and a quarter-on-quarter growth of 10.64%[19]. - The high-end hyaluronic acid product MaiLi®Extreme is set for commercialization in May 2025, featuring the innovative OxiFree™ technology[19]. - The company is advancing the registration and market launch of several new medical aesthetic products, including the V30 platform expected to receive approval by March 2025[29]. - The new filler MaiLi®Extreme received NMPA approval in January 2025, expanding the product line[29]. - The company is currently conducting safety follow-ups for the new hyaluronic acid filler MaiLi®Precise, which completed clinical trials in September 2024[29]. Equity and Shareholder Information - The company’s total equity attributable to shareholders increased by 4.33% to ¥24,059,686,522.62 from ¥23,060,051,397.36 at the end of the previous year[5]. - The number of ordinary shareholders at the end of the reporting period was 75,847, with no preferred shareholders having restored voting rights[11].

华东医药（000963）公告，2025年第一季度营收为107.36亿元，同比增长3.12%；净利润为9.15亿元， 同比增长6.06%。 ...